Treatment Option for Advanced Ovarian Cancer | ZEJULA (niraparib)
WEBZEJULA tablet is a prescription medicine used for the: maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.
GSK provides an update on Zejula (niraparib) US prescribing …
WEBNov 11, 2022 · NOVA is a randomised, double-blind, placebo-controlled phase III trial of niraparib, an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor for the maintenance treatment of women with platinum-sensitive recurrent ovarian cancer.
FDA approves Zejula (niraparib) as the only once-daily PARP ... - GSK
WEBApr 29, 2020 · Zejula is the only once-daily PARP inhibitor approved in the US as monotherapy for women with advanced ovarian cancer beyond those with BRCAm disease in the first-line and recurrent maintenance treatment settings, as well as late-line primary treatment settings.
U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for ...
WEBZEJULA is indicated: for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Expanded indication allows for treatment of women whose advanced ... - GSK
WEBGlaxoSmithKline (LSE/NYSE: GSK) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients ...
ESMO: GSK's Zejula, Pharma&'s Rubraca-Opdivo combo disappoint
WEBSep 14, 2024 · GSK’s Zejula boasts a broad U.S. approval as a first-line maintenance treatment for ovarian cancer patients who have responded to initial platinum-based chemotherapy. But the phase 3 study that ...
FDA approves Zejula (niraparib) as the only once-daily PARP ... - GSK
WEBApr 29, 2020 · Zejula is the only once-daily PARP inhibitor approved in the US as monotherapy for women with advanced ovarian cancer beyond those with BRCAm disease in the first-line and recurrent maintenance treatment settings, as well as late-line primary treatment settings.
WEBZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to ... - GSK
WEBSep 28, 2019 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy.
ZEJULA (niraparib) Patient Resources - Together with GSK …
WEBFind savings and support resources for ZEJULA (niraparib), including a co-pay assistance enrollment form and details on other ways to access your ZEJULA treatment.